AmpliPhi Biosciences Corporation To Present Research On Efficacy Of A Novel Bacteriophage Cocktail In S. Aureus Lung Infection Model At ICAAC/ICC 2015

SAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY--(BUSINESS WIRE)--AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that data comparing the efficacy of its bacteriophage cocktail to vancomycin in a Staphylococcus aureus lung infection mouse model will be presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting, September 17-21 in San Diego.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC